99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight

99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight

1. Basic Info

Product Name:	Orlistat
Synonyms:	(S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;XENICAL;(-)-TETRAHYDROLIPSTATIN;ORLISTAT;N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER;(-)-Tetrahydrolipstatin(EquivalentToOrlistat);Orlipastat
CAS:	96829-58-2
MF:	C29H53NO5
MW:	495.73
EINECS:	639-755-1
Product Categories:	Pharmaceutical Raw Materials;Miscellaneous Biochemicals;API;Antiobesity Agent;Chiral Reagents;Intermediates & Fine Chemicals;-;Pharmaceuticals;Amino Acids & Derivatives;Heterocycles;ACTOS;Other APIs;Lipid-lowering medicine reducing weight
Mol File:	96829-58-2.mol

2. Descriptions:

Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name by Roche in most countries, and is sold over-the-counter as by GlaxoSmithKline in the United Kingdom and the United States.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini.However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.

3. Applications:

Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.

The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).

Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. The effectiveness of orlistat in promoting weight loss is definite, Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

The effectiveness of orlistat in promoting weight loss is clear, albeit moderately. The pooled data from clinical trials show that people who give olivide have less than 2-3 kilograms (4.4-6.6 pounds) of medication than a year, except for changes in lifestyle such as diet and exercise. Is also a modest reduction in blood pressure, it seems to be able to prevent the onset of type 2 diabetes, whether due to weight loss itself or other effects; in a large randomized controlled trial, orlistat he was found in obese people will reduce the incidence of diabetes by nearly 40%

Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat.After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).

4. Orlistat COA

99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight